Mariner
AARD

Mariner’s Aardvark Therapeutics AARD Stock Holding History

Mariner’s Portfolio AARD Stock Details AARD Fund Activity
Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake 		Trade Value Portfolio Weight Portfolio Position
2026
Q2 		$125K Buy
+21,784
New +$102K ﹤0.01% 3285

Other funds holding AARD

DC
Decheng Capital Menlo Park, California $732M AUM 275.56% 1-Year Est. Return
Citadel Advisors
Citadel Advisors Miami, Florida $875B AUM 40.91% 1-Year Est. Return
LCM
Laurion Capital Management New York $3.9B AUM 75.03% 1-Year Est. Return
Vanguard Capital Management
Vanguard Capital Management Malvern, Pennsylvania $4.68T AUM
AQR Capital Management
AQR Capital Management Greenwich, Connecticut $287B AUM 42.33% 1-Year Est. Return
EC
EcoR1 Capital San Francisco, California $2.06B AUM 215.32% 1-Year Est. Return
Adage Capital Partners
Adage Capital Partners Boston, Massachusetts $71.3B AUM 56.8% 1-Year Est. Return
BlackRock
BlackRock New York $6.73T AUM 46.02% 1-Year Est. Return
Geode Capital Management
Geode Capital Management Boston, Massachusetts $1.88T AUM 44.46% 1-Year Est. Return
CF
Cantor Fitzgerald New York $9.31B AUM 73.66% 1-Year Est. Return

Mariner's AARD Position: Q2 2026 in Review

Mariner opened a new position in Aardvark Therapeutics (AARD) in Q2 2026: 21,784 shares worth $125K. The stake represents ﹤0.01% of the portfolio and ranks #3285 among its holdings.

72 funds tracked by Wall St. Rank hold AARD as of Q2 2026.

  • Mariner held 21,784 shares of Aardvark Therapeutics worth $125K as of Q2 2026.
  • Aardvark Therapeutics was a new Mariner position in Q2 2026.
  • Aardvark Therapeutics made up ﹤0.01% of Mariner's portfolio in Q2 2026, its #3285 holding.
  • 72 funds tracked by Wall St. Rank held Aardvark Therapeutics as of Q2 2026.

Based on Mariner's 13F filing for Q2 2026, filed 13 Aug 2026.